Autopsy report · NCT00607438

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

“Low accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 1 year 8 months before it stopped.
• 16 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Veeda Oncology

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane); Sorafenib (Nexavar)

Participants

16

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.